ERCC1 and ovarian cancer: A meta-analysis by Yang et al. in 2019 [45] showed that ERCC1 rs11615 polymorphism was not associated with chemosensitivity in patients with ovarian cancer, and a subgroup analysis of the Asian population showed the same conclusion.